|

Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation

RECRUITINGSponsored by University Hospital Pilsen
Actively Recruiting
SponsorUniversity Hospital Pilsen
Started2026-08-01
Est. completion2028-12-31
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07570407

Summary

The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosis: AML (exlusion of secondary disease)
* Disease status at time of HSCT: complete remission
* Karnofsky performance status: ≥80%
* Source of HSC: PBSC

Exclusion Criteria:

* Prior transplant
* Uncontrolled Malignancy

Conditions6

Acute Myeloid LeukemiaAllogeneic HSCTCancerGVHDPosttransplant ComplicationsRelapse

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.